Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00652106 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
- 1
- Study location
NCT00652106: Completed Phase 3 study of Glaucoma and Ocular Hypertension, sponsored by Allergan.
NCT00652106 is a Phase 3 study of Glaucoma and Ocular Hypertension that has completed, run by Allergan. The registered enrollment target is 432 participants, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00652106, a Phase 3 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions
Conditions Studied
Interventions
- DRUG 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
- DRUG Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
- DRUG Brimonidine 0.2% ophthalmic solution
Study Locations (1)
Texas
- - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2003-06 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00652106 record still lists
NCT00652106 is an interventional study that assigns participants to a tested intervention. The registered 432 participants enrollment target is mid-sized for trials with a published cap, below the 906-participant average among 92 other Glaucoma trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution is the first listed.
NCT00652106 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00652106 about?
NCT00652106 is a clinical study titled "Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions
What is the current status of trial NCT00652106?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2003-06. Estimated completion is 2004-03.
What conditions does trial NCT00652106 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT00652106?
The interventions under investigation include: 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution (DRUG), Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution (DRUG), Brimonidine 0.2% ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00652106?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00652106 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00652106's enrollment target sits among peer trials
432 13th of 92 higher than 80 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilocarpine Use After Kahook Goniotomy
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05271240 · 432 participants · Phase 3
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
- NCT05365815 · 432 participants · NA
Melanated Group Midwifery Care (MGMC)
- NCT05499507 · 432 participants · NA
The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)
- NCT05806164 · 432 participants · Phase 4
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia